Scientists discover important cancer defence switch

December 14, 2011
Scientists discover important cancer defence switch
A natural killer cell (green) surveys two potential target cells (red) for signs of disease

(Medical Xpress) -- A multi-disciplinary team of researchers at King’s College London have captured the first live images of a key molecular switch in the body’s natural defence system against tumour cells.

Published recently in the journal Science Signaling, the study looked at a type of white blood cell, called a Natural Killer (NK) cell. These are immune cells that protect the body by identifying and killing infected and diseased cells.

is known to evade the normal immune response by suppressing ‘distress’ signals monitored by immune cells. Recently, there has been a new emphasis on treatments that can improve a patient’s own anti-tumour immunity by interfering with the signals within anti-tumour immune cells. But the precise nature of signalling between cells at the exact point when immune cells engage the cancer cells is difficult to demonstrate without imaging.

Experts from different disciplines across King’s, including: the Randall Division of Cell & Molecular Biophysics; Division of Cancer Studies; Departments of Mathematics and Physics; as well as from the Gray Institute for Radiation Oncology and Biology (University of Oxford), came together to study these interactions, and to image the regulation of a key molecular switch (Cdc42) in NK cells for the first time. This molecular switch, Cdc42, is important for activating the cell’s surveillance system that searches for and destroys cancer cells.

The researchers discovered that an important group of enzymes (PI-3 kinases) play a key regulatory role on Cdc42 in NK cells.

PI-3 kinases are currently being explored in trials as a potential target for cancer treatment. Therefore the researchers warn that if PI-3 kinases are inhibited to treat a tumour, the immune system’s natural killer mechanisms may also be inhibited. This means that although there is good scientific evidence for targeting PI-3 kinases in cancers, trials exploring these potential treatments should take the findings of this study into account.

Professor Tony Ng, Richard Dimbleby Chair of Cancer Research, Head of Cell Biology and Imaging in the Division of Cancer Studies at King’s, said: ‘This is an exciting finding, which helps us better understand the body’s own natural defences against cancer. It is vital that these findings are taken on board by those currently carrying out trials to look at PI-3 kinases, so they can monitor the impact of these potential therapies on the immune system.’

Dr Leo Carlin who was part of Professor Ng’s team during the study, said: ‘We have been able to directly visualise not only the location of important molecules in NK cell function, but also whether they are switched on or not.  A cross-disciplinary approach also allowed us to intelligently screen for key regulators of these molecular switches.’

Explore further: Stem cell approach primes immune system to fight cancer

Related Stories

Recommended for you

Study examines evolution of cancer

February 8, 2016

A novel Yale study answers age-old questions about how cancers spread by applying tools from evolutionary biology. The new insights will help scientists better understand the genetic origins of tumor metastases, and lead ...

The growing menace of HPV‑related throat and mouth cancers

February 2, 2016

There's a new cancer epidemic on the rise. It's an aggressive throat and mouth cancer caused by the human papillomavirus (HPV)—the same sexually transmitted virus that leads to cervical cancer—but it's affecting mostly ...

How gut inflammation sparks colon cancer

February 4, 2016

Chronic inflammation in the gut increases the risk of colon cancer by as much as 500 percent, and now Duke University researchers think they know why.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.